Helocyte Inc. (“Helocyte”), a portfolio company of Fortress Biotech is focused on the development and commercialization of novel immunotherapies for the prevention and treatment of cancer and infectious disease ( in particular, cytomegalovirus or “CMV”) 

 

pipeline-slide

Press Releases

October 28, 2016

Data from Phase 1 Trial of Triplex Vaccine for Control of Cytomegalovirus Published in Blood

Triplex Demonstrated Favorable Safety and Immunogenicity at Multiple Dose Levels in Healthy Volunteers Data Published in Blood Support Ongoing Phase 2 Trial of Triplex in Allogeneic Hematopoietic Stem Cell Transplant Recipients DUARTE, Calif., and NEW YORK, Oct. 28, 2016 (GLOBE NEWSWIRE) — City of Hope, a world-renowned independent research and cancer treatment center, and Helocyte,

April 21, 2016

HELOCYTE ANNOUNCES CORPORATE AND CLINICAL MILESTONES

HELOCYTE ANNOUNCES CORPORATE AND CLINICAL MILESTONES Frank Taffy Appointed President and Chief Executive Officer Lead Immunotherapies PepVax and Triplex Advanced into Phase 2 Triplex Phase 1 Data Presented at ASH PepVax Phase 1b Data Published in The Lancet New York, New York – April 21, 2016 – Helocyte, Inc. a majority-owned subsidiary of Fortress Biotech,

April 2, 2015

FORTRESS BIOTECH (f/k/a Coronado Biosciences) FORMS NEW SUBSIDIARY, HELOCYTE, INC. (f/k/a DiaVax Biosciences) TO DEVELOP NOVEL IMMUNOTHERAPIES FOR CYTOMEGALOVIRUS

FORTRESS BIOTECH FORMS NEW SUBSIDIARY, HELOCYTE, INC., TO DEVELOP NOVEL IMMUNOTHERAPIES FOR CYTOMEGALOVIRUS